Drugs / Allogeneic Stem Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00282438 | Dec 2003 → Aug 2015 | sarcoidosis | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT05675319 | Mar 2023 → Mar 2025 | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Stem Cells | “Allogeneic stem cells will be injected after conditioning” NCT00282438 ↗ |
| Modality | Cell therapy | “Allogeneic stem cells will be injected after conditioning” NCT00282438 ↗ |
| Route | Other | “Allogeneic stem cells will be injected after conditioning” NCT00282438 ↗ |